IgA肾病患者血清IgA及治疗前后尿液IL-6水平改变的临床价值

Detection and Clinical Significance of Changes of Serum IgA and Urinary Interleukin-6 Levels after Treatment in Patients with IgA Nephropathy

目的 探讨IgA肾病（IgA nephropathy,IgAN）患者血清IgA和尿液白细胞介素-6（urinary interleukin-6,uIL-6）水平的应用价值及疗效判断中的临床意义.方法 应用乳胶增强散射比浊技术及酶联免疫（ELISA）法测定63例IgAN患者和30例健康对照者血清IgA及尿液IL-6水平,同时对检测结果进行分析.结果 IgAN患者血清IgA为（2.23±0.87）g/L及uIL-6水平（29.05±2.63）ng/L明显高于健康对照组（1.43±0.50）g/L和（20.22±4.38）ng/L,差异有统计学非常显著性意义（P＜0.01）;IgAN患者治疗前、后uIL-6水平差异显著（P＜0.05）;尿液中白细胞增加和血尿伴蛋白尿的IgAN患者uIL-6水平与健康对照组相比差异非常显著（P＜0.01）;IgAN患者治疗前、后uIL-6水平比较差异非常显著（P＜0.01）;单纯性血尿的IgAN患者治疗后的uIL-6水平与健康对照组无显著性差异（P＞0.05）.结论 IgAN患者血清IgA及uIL-6水平明显高于健康对照组,uIL-6检测可以作为IgAN肾小球损伤向慢性化进展的一项指标.IgAN患者治疗前后uIL-6水平的改变对疗效的观察及预后判断具有一定的临床价值.

Objective To explore the elinieal values of between clinical usefulness of serum IgA and urinary interleukin-6 （uIL-6） level changes after treatment to evaluate predict and disease progress in patients with IgA nephropathy（IgAN）. Methods 63 patients with IgAN and 30 healthy subjects were detected the urinary level of IL-6 by ELISA and the IgA was determined by nephe-tometric immunoassay. Analysis were those of detection results. Results The serum IgA levels was （2.23±0. 87）g/L and uIL-6 levels was （29.05±2.63）ng/L of patient group,that was significantly higher than that of healthy control group （1.43±0.50） g/L and （20.22±4.38）ng/L （P〈0.01）. Changes of uIL-6 levels was significantly higher than that after treatment in patients with IgAN （P〈0. 05）. Urinary IL-6 levels were statistically significance differences of white blood corpuscle to increased in urinary and blood urine to accompany urinary protein with IgAN （P〈 0.01 ）. Urinary IL-6 levels were not significantly correlated than that after treatment in patients with IgAN presenting with isolated hematuria than that of healthy control （P〉0. 05）. Conclusion The serum IgA and uIL-6 levels of patient group was significantly higher than that of healthy control group. Measurement of uIL-6 was a useful marker in evaluating during development in patients with IgAN. The changes of levels uIL-6 after treatment in patients with IgAN could reflect renal injures and could serve as a useful indicator in evaluating the prognosis of patients with IgAN.